Search PubMed⌕ Search

Biomedical subjects

G S Johnson

Publications and source records attributed to G S Johnson.

At least 127 records · Page 7Linked to original sources
PubMed1981

Binding of low-molecular-weight canine factor VIII coagulant from von Willebrand plasma to canine factor VIII-related antigen.

Plasmas having no detectable factor VIII-related antigen but moderate factor VIII coagulant were obtained from two unrelated dogs homozygous for von Willebrand's disease and with the severe clinical expression of the disease. when these plasmas were gel-filtered in a buffer at physiologic ionic strength, the factor VIII coagulant eluted in the bed volume as a single well-defined peak. Addition of protease inhibitors, including diisopropylfluorophosphate, did not change the elution pattern. Each plasma was then combined individually with plasmas from six different mutants of canine haemophilia, all of which had normal factor VIII-related antigen but no detectable factor VIII coagulant. The factor VIII coagulant elution profile of these combined plasma resembled that of normal canine plasma. Slightly over half of the recovered factor VIII coagulant coeluted in the void volume with the factor VIII-related antigen; the rest eluted as a second, distinct peak of lower molecular weight. These results demonstrated that part of the factor VIII coagulant of the von Willebrand plasmas had bound to the factor VIII-related antigen of the haemophilic plasmas. This finding supports the theory that factor VIII exists as a macromolecular complex of nonidentical components in normal citrated plasma.

Animals↗
PubMed1981

Accumulation of circulating macrophages in lungs of guinea pigs exposed to hyperoxia.

Superoxide dismutase (SOD) and glutathione peroxidase (GPx) key enzymes in alveolar macrophages regulating levels of superoxide anion and hydrogen peroxide, respectively, were observed to fluctuate in response to FIO2 of 50 and 85% for 18 to 90 hr. At the lower oxygen tension, SOD rose two-fold and GPx decreased significantly by 18 hr and throughout the exposure periods compared to a delayed increase in SOD activity which was not sustained beyond 66 hr of exposure and a sustained rise in GPx to an FIO2 of 85%. Peritoneal macrophages containing lower SOD activity and greater GPx activity than resident alveolar macrophages upon injection into the circulation resulted in 10-fold accumulation in the lungs during exposure of animals to FIO2 of 85% but not at 50%. This study indicates that brief exposure to FIO2 of 85% but not 50% resulted in alterations of the vascular integrity of the lungs resulting in the accumulation of circulating macrophages to the alveolar macrophage pool. The delayed rise in SOD activity and the sustained increase in GPx activity in alveolar macrophages from animals exposed to FIO2 of 85% could in part be related to this influx of circulating macrophages with enzymatic characteristics observed for peritoneal macrophages.

Animals↗
PubMed1981

Large potentiation of agonist response in intact cells is produced by increases only in GTP-dependent adenylate cyclase activity.

Treatment of cultured SV40-transformed normal rat kidney cells with the drug, 2-pyridine carboxylic acid, results in a pronounced potentiation in the ability of isoproterenol, prostaglandin E1, and cholera toxin to elevate cyclic AMP levels. With isoproterenol, the initial rate of cyclic AMP accumulation and the maximum cyclic AMP attainable are increased, and also the time of maximum cyclic AMP is prolonged. GTP-dependent adenylate cyclase activities are potentiated in crude membranes from the treated cells, but no evidence for alterations in cyclic nucleotide phosphodiesterase or release of cyclic AMP into the medium could be demonstrated. Results show that augmented adenylate cyclase activity alone, without changes in phosphodiesterase, can lead to dramatic alterations in cyclic AMP accumulation in response to cyclase agonists.

3',5'-Cyclic-AMP Phosphodiesterases↗
PubMed1980

A bleeding disease (von Willebrand's disease) in a Chesapeake Bay Retriever.

A bleeding disease similar to von Willebrand's disease in man was diagnosed in a 6-month-old Chesapeake Bay Retriever with recurrent, protracted gingival hemorrhage that responded rapidly to fresh, whole blood transfusions. The dog had a prolonged bleeding time and low plasma factor VIII coagulant activity (18%). The plasma had no detectable factor VIII-related antigen or von Willebrand factor, as measured by ristocetin-cofactor and polybrene-cofactor activities. The dam of the dog had a plasma factor VIII-related antigen concentration (32%) well below the normal range. The antigen in the sire's plasma was at the low end of the normal range, as was the polybrene-cofactor of both the sire and the dam. These data suggested an inherited basis for von Willebrand's disease in this dog.

Animals↗
PubMed1980

Metabolism of NAD and N1-methylnicotinamide in growing and growth-arrested cells.

Nicotinamide is metabolized primarily into NAD and N1-methylnicotinamide in cultured cells of normal rat kidney. The metabolic pathways for the nicotinamide metabolites are independently regulated and are influenced by the growth stage of the cells. N1-Methylnicotinamide levels are 1.5--2-fold elevated in cells growth-arrested by treatment with histidinol, thymidine, or picolinic acid, or by serum starvation. This increase is due to a more rapid rate of synthesis rather than decrease in excretion. The rates of both synthesis and degradation of NAD are increased in serum-starved cells so that the NAD concentration is the same as it is in growing cells. NAD and N1- methylnicotinamide levels are not significantly increased when the intracellular nicotinamide concentration is increased 20-fold by addition of excess nicotinamide to the culture medium, demonstrating that the size of the nicotinamide pool does not limit synthesis of these compounds. In medium containing normal amounts of nicotinamide, the apparent first-order rate constant for the decay of NAD, radioactively labeled in the nicotinamide moiety, is about 4 h-1. Labeled N1-methylnicotinamide is not metabolized, but rather is excreted into the medium with a first-order rate constant of 3.9 h-1. The rate of loss of label from NAD, but not from N1-methylnicotinamide, is increased about twofold by addition of excess nicotinamide to the culture medium. This could be explained by a dilution of a labeled nicotinamide pool which is formed during NAD degradation and which is recycled into NAD but not into N1-methylnicotinamide. The results demonstrate a rapid turnover of NAD at the bond joining nicotinamide and ADP-ribose, in agreement with previous studies. In addition, the results show that nicotinamide is metabolized into N1-methylnicotinamide with what appears to be a carefully regulated synthetic mechanism. The existence of significant amounts of N1-methylnicotinamide in cultured cells raises the question of the physiological importance of this compound.

Animals↗
PubMed1980

Measurement of canine von Willebrand factor using ristocetin and Polybrene. Diagnosis of canine von Willebrand's disease.

Dogs with VWD provide useful models for the study of the factor VIII complex. However, the study of canine VIIIR:WF has been hampered by the lack of a routine plasma assay for canine RCF, an activity that is usually used as a measure of VIIIR:WF. This study shows that canine plasma can be assayed for RCF with a macroscopic tilt-tube method using formalin-fixed human platelets, ristocetin, and extra canine albumin (5.0 mg/ml) to prevent plasma precipitation. An assay was also developed for canine plasma PBCF, an activity that is closely related to RCF. In 45 normal canine plasmas, VIII:C was not correlated with RCF, PBCF, or VIIIR:AG. However, RCF, PBCF, and VIIIR:AG were well correlated with each other. In 26 canine VWD plasmas, VIII:C was frequently normal, whereas VIIIR:AG, RCF, and PBCF were almost always deficient. The patterns of VIIIR:AG, RCF, and PBCF deficiencies in the canine VWD plasmas suggested that some canine breeds have a "classic" form of VWD whereas other breeds have "variant" forms of disease.

Animals↗
PubMed1979

Enhancement of hormonal stimulation in intact cells. Potentiation of GTP-dependent activation of adenylate cyclase.

The ability of prostaglandin E1 (PGE1) and cholera toxin to increase cyclic AMP levels is potentiated 6-fold when normal rat kidney (NRK) cells are treated with picolinic acid or histidinol, or grown in isoleucine-deficient medium. The response to (-)-isoproterenol is increased 2-fold in NRK cells treated with picolinic acid but not in cells subjected to isoleucine deprivation. The increase in agonist responsiveness is time-dependent, reaches its maximum at 40 h, and is quickly reversed following removal of picolinic acid or addition of medium with normal amounts of isoleucine. The cholera toxin response is also increased about 7-fold in simian virus 40-transformed NRK cells and Moloney sarcoma virus-transformed NRK cells treated with picolinic acid. GTP-stimulated, but not fluoride-stimulated, adenylate cyclase activities are increased in membranes from NRK cells treated with picolinic acid or starved for isoleucine, indicating that the increased response is due, at least in part, to a specific potentiation of GTP-dependent functions of the adenylate cyclase system. The results demonstrate that GTP-dependent events in hormonal stimulation of adenylate cyclase can be altered in intact cells to modulate hormonal enhancement of cyclic AMP production.

Adenylyl Cyclases↗
PubMed1979

Role of the spoT gene product and manganese ion in the metabolism of guanosine 5'-diphosphate 3'-diphosphate in Escherichia coli.

Addition of divalent ion chelating agents picolinic acid, 1,10-phenanthroline, or quinoline-2-carboxylic acid to wild type, relA, or relX, but not spoT strains of Escherichia coli increases the levels of guanosine 5'-diphosphate 3'-diphosphate (ppGpp). Poorly chelating analogs of these agents and a larger and more highly charged chelating agent, ethylene glycol bis(beta-amino-ethyl ether) N,N,N',N'-tetraacetic acid are ineffective. Mn2+ reverses the increase in ppGpp. The increase in ppGpp in wild type cells can be explained by an inhibition of degradation. In spoT cells the response is more complex; ppGpp does not increase although degradation is completely inhibited. The lack of increase in spoT cells suggests a role for spoT in synthesis of ppGpp in addition to its known role in degradation. Growth of both spoT+ and spoT cells is inhibited following chelator addition. This suggests that growth inhibition is through a mechanism not directly involving ppGpp. The results of this study provide evidence in intact cells for a role for Mn2+ and the spoT gene product in ppGpp degradation, and provide further evidence for an involvement of spoT and possibly divalent ions in ppGpp synthesis.

Alleles↗
PubMed1979

Evidence in intact cells for an involvement of GTP in the activation of adenylate cyclase.

Treatment of cultured normal rat kidney cells with virazole or mycophenolic acid which are inhibitors of IMP dehydrogenase decreases by 50 to 70% the ability of prostaglandin E1 or isoproterenol to elevate cAMP levels. Inhibition is maximal by 2 h. The response to cholera toxin is not significantly decreased. Basal cAMP is not affected. Under these conditions, GTP is decreased by 80%, ATP is only 10 to 15% decreased, and UTP and CTP are slightly increased. Normal GTP levels and the responses to prostaglandin E1 and isoproterenol are restored if guanosine, but not inosine, is added with the inhibitor. The response to isoproterenol is recovered within 5 min after removal of mycophenolic acid. Desensitization to prostaglandin E1 or isoproterenol stimulation occurs under conditions where GTP is 80% decreased. These results in intact cells provide direct evidence for a role for GTP in the activation of adenylate cyclase and support previous conclusions from studies with cell homogenates.

Adenosine Triphosphate↗
PubMed1979

Transient growth inhibition of Escherichia coli K-12 by ion chelators: "in vivo" inhibition of ribonucleic acid synthesis.

The ion chelators picolinic acid, quinaldic acid, 1,10-phenanthroline, and 8-hydroxyquinoline, but not ethylenediaminetetraacetate, ethyleneglycol-bis-(beta-aminoethyl ether)-N,N-tetraacetate, or dipicolinic acid, rapidly but transiently arrest growth of Escherichia coli K-12. Cells adapt and become resistant to growth inhibition by these agents, a process which requires protein synthesis. Mn2+, at low concentrations, decreases the time required for resumption of growth. Proteins synthesized during the lag are quantitatively and qualitatively different from those synthesized during normal growth. Inhibition of growth can explained by an effect on RNA polymerase, a known metalloenzyme.

Adaptation, Physiological↗
PubMed1979

Increase in hormonal activation of adenylate cyclase by treatment of cultured cells with N-alkyl,N-nitrosourea.

Treatment of cultured normal rat kidney cells with the nitrosourea-containing compounds streptozotocin, chlorozotocin, or 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea resulted in a time-dependent potentiation in the ability of prostaglandin E1 and (-)-isoproterenol to elevate intracellular cAMP levels. This hormone response increased at 4 hours and reached a maximum at 15--25 hours after addition of the nitrosoureas. Basal cAMP levels were not affected. The greater response was apparently due to an increase in the GTP-dependent step in hormonal activation of adenylate cyclase, inasmuch as GTP- and GTP plus hormone-stimulated adenylate cyclase activities were enhanced twofold to threefold in crude membranes prepared from nitrosourea-treated cells. Fluoride-stimulated adenylate cyclase activity was increased only 10--25%. Nicotinamide did not prevent the elevated response, and NAD+ plus NADH levels were not appreciably altered after 42 hours; treatment with streptozotocin. The results suggest a possible involvement of cAMP in the biologic actions of nitrosoureas.

Adenylyl Cyclases↗